CD274 and neoplasm: Complete response rate. Other anti-tumour activity data: ORR: 55.3%, DCR: 84.2% in ITT population, ORR: 66.7% in PD-L1-positive, 47.8% in PD-L1-negative patients. DCR: 91.7% in PD-L1-positive, 78.3% in PD-L1-negative patients